Neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors：NEO-ERA-01 Study

This study is testing a new combination of chemotherapy and targeted therapy to see if it helps people with a specific type of liver cancer avoid recurrence after surgery.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: The First Affiliated Hospital with Nanjing Medical University (Academic / other)
• Drugs / interventions: Lenvatinib, chemotherapy, prednisone, Adebrelimab, immunotherapy
• Locations: 3 sites (Nanjing, Jiangsu and 2 other locations)
• Trial ID: NCT06208462 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of a combination of hepatic artery infusion chemotherapy (HAIC) with Gemcitabine and Oxaliplatin, alongside Lenvatinib and Adebrelimab, for patients with resectable intrahepatic cholangiocarcinoma (ICC) who have high-risk recurrence factors. The study aims to determine whether this neoadjuvant therapy can improve outcomes for patients who are at risk of tumor recurrence after surgical resection. Participants will be closely monitored for their response to treatment and any potential side effects.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with pathologically diagnosed resectable ICC and high-risk factors for recurrence.

Not a fit: Patients with unresectable ICC or those who do not meet the specified inclusion criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the recurrence rate of intrahepatic cholangiocarcinoma after surgery.

How similar studies have performed: While some studies have shown promise with similar approaches, the specific combination of therapies in this trial is novel and has not been extensively tested in resectable ICC.

Eligibility criteria

Inclusion Criteria:

1. The patient must sign the informed consent;
2. Age 18-75 years old, male and female;
3. ECOG Physical status Score (PS score) 0 or 1;
4. Patients with ICC who have been pathologically diagnosed (histopathological and/or cytological examination) or clinically diagnosed as having high-risk factors;

   Risk factors are defined as follows:

   Stage ≥Ib, single lesion \> 5cm, multiple tumor lesions in the same lobe, technically resectable;Vascular invasion, regional lymph node metastasis, technically resectable
5. Patients with untreated and resectable locally advanced ICC who have been assessed by the surgeon as surgically resectable;
6. The functional indicators of vital organs meet the following requirements

   ① Neutrophils ≥1.5\*109/L; Platelet ≥80\*109/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl;② Thyroid stimulating hormone (TSH) ≤ 1 times the upper limit of normal, T3, T4 in the normal range;③ Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤ 2 times the upper limit of normal value;④ Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min;
7. The subject has at least one measurable lesion (according to RECIST1.1);
8. Fertile women: must agree to abstain from sex (abstain from heterosexual intercourse) or use a reliable, effective method of contraception for at least 120 days from the signing of the informed consent until the final administration of the study drug. Serum HCG test must be negative within 72 hours before randomization. And must be non-lactating.A woman is considered fertile if she has menstruated, has not yet reached postmenopausal status (no continuous periods for ≥12 months, no cause other than menopause has been found), and has not undergone sterilization (such as hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
9. For male subjects whose partner is a fertile woman, they must agree to abstain from sex or use a reliable, effective method of contraception for at least 120 days from the signing of the informed consent until the final administration of the study drug. Male subjects also had to agree not to donate sperm during the same time period. Male subjects with a pregnant partner are required to use condoms and do not need to use other methods of contraception.

Exclusion Criteria:

1. Pathological diagnosis of hepatocellular carcinoma, mixed hepatocellular carcinoma and other non-cholangiocarcinoma malignant tumor components;
2. Prior systemic therapy and tumor-related surgical treatment (biliary drainage allowed);Patients who relapse after surgery, have received PD1 antibody, PDL1 antibody or CTLA4 antibody, Lenvatinib, chemotherapy in the past; participated in other clinical trials 30 days before screening
3. Previous or co-existing malignancies other than adequately treated non-melanin skin cancer, cervical carcinoma in situ and thyroid papillary carcinoma;
4. Active pulmonary tuberculosis infection. Patients with active pulmonary tuberculosis infection within 1 year prior to enrollment; Had a history of active tuberculosis infection more than 1 year before enrollment, had not received formal anti-tuberculosis therapy or had active tuberculosis;
5. Have an active, known, or suspected autoimmune disease. Subjects with hypothyroidism requiring hormone replacement therapy and skin conditions that do not require systemic therapy are eligible;
6. Long-term acceptance of systemic sex hormones (doses equivalent to \> 10mg prednisone per day) or any other form of immunosuppressive therapy. Participants using inhaled or topical corticosteroids may be enrolled;
7. Severe cardiopulmonary and renal dysfunction;
8. Have hypertension that is not well controlled by antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg);
9. Abnormal coagulation function (PT\> 14s), have a tendency to bleed or are receiving thrombolytic or anticoagulant therapy;
10. HBV DNA\> 2000IU/ml, HCV RNA\> 1000 IU/ml;
11. Had clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;
12. Active infections that require systemic treatment;
13. Human immunodeficiency virus (HIV, HIV1/2 antibodies) positive;
14. Have a history of psychotropic substance abuse, alcohol abuse or drug use;
15. Have a history of drug allergy;
16. Other factors, as determined by the investigator, that may affect the subject's safety or compliance with the test. Such as a serious illness (including mental illness) requiring co-treatment, serious laboratory abnormalities, or other family or social factors.

Where this trial is running

Nanjing, Jiangsu and 2 other locations

• The First Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
• West China Hospital — Chengdu, Sichuan, China (Recruiting)
• Ningbo Medical Center Lihuili Hospital — Ningbo, Zhejiang, China (Recruiting)

Study contacts

• Study coordinator: Feng Cheng, MD

Conditions Intrahepatic Cholangiocarcinoma